NEWSROOM
Stay current with MiRXES
Featured
Media Releases
Keep up to date with our latest news and activities as we continue to innovate and develop our science and technology, bringing novel products to market. – from Singapore to the world.
Date: 06-10-2021
MiRXES announced today the appointment of Mr. Cher Hwa TEO as Senior Vice President (SVP), Health Innovation Delivery and Chief of Staff. As the SVP of Health Innovation Delivery, Mr. Teo will help embed MiRXES into the Singapore healthcare ecosystem through downstream market access efforts by driving greater advocacy towards the adoption of MiRXES’s technology and products.
Date: 06-10-2021
MiRXES announced today the appointment of Mr. Da LIU to its Board of Directors. Currently the Managing Director of CR-CP Life Science Fund, Mr. Liu leads investments in life sciences companies globally, especially those in emerging sectors such as RNA therapeutics and cancer screening.
Date: 06-10-2021
MiRXES announced today the appointment of Dr. David CAPES as Senior Vice President and Global Head of Innovation. In this newly created role, Dr. Capes will focus on the transformation of MIRXES from a regional SME to a global innovation enterprise over the next three years
Date: 06-10-2021
Dr Holger Heyn, an expert in single-cell genomics and spatial transcriptomics, has joined the Scientific Advisory Board of MiRXES to help advance its development of RNA-powered multi-omics solutions for research and diagnostics
Date: 06-10-2021
This new capital will support MiRXES’s growth as a global leader in cancer early detection tests and preventive healthcare
Date: 06-10-2021
This study shows MiRXES qPCR profiling platform to be superior in reproducibility and detection rate compared to other commercial microRNA profiling platforms when used for validation of blood-based microRNA biomarkers.
Date: 06-10-2021
This study shows MiRXES qPCR profiling platform to be superior in reproducibility and detection rate compared to other commercial microRNA profiling platforms when used for validation of blood-based microRNA biomarkers.
Date: 06-10-2021
This study shows MiRXES qPCR profiling platform to be superior in reproducibility and detection rate compared to other commercial microRNA profiling platforms when used for validation of blood-based microRNA biomarkers.
Date: 06-10-2021
This study shows MiRXES qPCR profiling platform to be superior in reproducibility and detection rate compared to other commercial microRNA profiling platforms when used for validation of blood-based microRNA biomarkers.
Date: 06-10-2021
This study shows MiRXES qPCR profiling platform to be superior in reproducibility and detection rate compared to other commercial microRNA profiling platforms when used for validation of blood-based microRNA biomarkers.
Media Coverage
Stay informed and keep abreast with our media news.
08/07/2021
MiRXES has raised US$77 million in a Series C round, pushing to commercialise its early cancer detection test kits globally. This latest round values the biotech at over US$500 million and could pave the way for a public listing.
31/03/2021
This latest FT ranking of 500 of the region’s high-growth companies is compiled in partnership with Nikkei Asia and research provider Statista. MiRXES is ranked 194 position, and top 30 in Singapore.
31/03/2021
This latest FT ranking of 500 of the region’s high-growth companies is compiled in partnership with Nikkei Asia and research provider Statista. MiRXES is ranked 194 position, and top 30 in Singapore.
31/03/2021
This latest FT ranking of 500 of the region’s high-growth companies is compiled in partnership with Nikkei Asia and research provider Statista. MiRXES is ranked 194 position, and top 30 in Singapore.
31/03/2021
This latest FT ranking of 500 of the region’s high-growth companies is compiled in partnership with Nikkei Asia and research provider Statista. MiRXES is ranked 194 position, and top 30 in Singapore.
31/03/2021
This latest FT ranking of 500 of the region’s high-growth companies is compiled in partnership with Nikkei Asia and research provider Statista. MiRXES is ranked 194 position, and top 30 in Singapore.
Collaborations
Our partnerships
15 Sep 2021
ヒューマン・メタボローム・テクノロジーズ株式会社
代表取締役社長 橋爪 克仁 、 本社 山形県鶴岡市、以下「 HMT 」 と 、 MiRXES （ミレックサス Chief Executive Officer Zhou Lihan 、本社： シンガポール 、以下「 MiRXES 」 は、 マイクロ RNA 関連製品・サービスを日本において展開することに合意し、販売契約を締結しました 。
31 Aug 2021
大阪国際がんセンター（以下、当センター）は、希少疾患の一つである成人T細胞白血病リンパ腫※1（以下、ATL）のデータベースを拡充、整備することにより、早期診断や新たな診断指標の探索、それを活用した診断法の開発を推進することを主な目的として、当センター内と外部関連機関による共同研究を2021年5月19日※2より開始いたしました。
31 Aug 2021
大阪国際がんセンター（以下、当センター）は、希少疾患の一つである成人T細胞白血病リンパ腫※1（以下、ATL）のデータベースを拡充、整備することにより、早期診断や新たな診断指標の探索、それを活用した診断法の開発を推進することを主な目的として、当センター内と外部関連機関による共同研究を2021年5月19日※2より開始いたしました。
31 Aug 2021
大阪国際がんセンター（以下、当センター）は、希少疾患の一つである成人T細胞白血病リンパ腫※1（以下、ATL）のデータベースを拡充、整備することにより、早期診断や新たな診断指標の探索、それを活用した診断法の開発を推進することを主な目的として、当センター内と外部関連機関による共同研究を2021年5月19日※2より開始いたしました。
31 Aug 2021
大阪国際がんセンター（以下、当センター）は、希少疾患の一つである成人T細胞白血病リンパ腫※1（以下、ATL）のデータベースを拡充、整備することにより、早期診断や新たな診断指標の探索、それを活用した診断法の開発を推進することを主な目的として、当センター内と外部関連機関による共同研究を2021年5月19日※2より開始いたしました。
31 Aug 2021
大阪国際がんセンター（以下、当センター）は、希少疾患の一つである成人T細胞白血病リンパ腫※1（以下、ATL）のデータベースを拡充、整備することにより、早期診断や新たな診断指標の探索、それを活用した診断法の開発を推進することを主な目的として、当センター内と外部関連機関による共同研究を2021年5月19日※2より開始いたしました。
Insights
Welcome to our knowledge base of insights in the frontiers of the biotech industry.
Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats—to great success.
As the world’s first molecular blood test for detecting gastric cancer, GASTROClear could play a pivotal role in stopping the deadly disease in its earliest stages.
Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats—to great success.
Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats—to great success.
Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats—to great success.
Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats—to great success.
Media and Investor Contact
For media enquiries, please email: communications@mirxes.com
SOCIAL MEDIA
- Genomics
- Clinical Sequencing
- Research Sequencing
- Cancer Screening
- GASTROClear for Patients
- GASTROClear for Medical Professionals
- Cancer Treatment Selection
- APEX Tissue Panel for Medical Professionals
- Infectious Diseases
- Fortitude 2.1
- Fortitude 3.0
- Fortitude Syndromic Panel
- CoVClear Mutation Panel
- Swab & Saliva Collection
- RNA Extraction Kit & Instruments